Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CC-4047 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| CC-4047 | DRUG | - |
Inclusion Criteria: * Understand and voluntarily sign an informed consent form * Adult male subjects, age 18 or older at the time of signing the informed consent form * Able to adhere to the study visit schedule and other protocol requirements * Histologically confirmed adenocarcinoma of the prosta...
Top 20 of 53 competitors
CC-4047 is a small molecule being studied for the treatment of prostate cancer, specifically metastatic hormone refractory prostate cancer (HRPC). It is an investigational drug in Phase 2 clinical development, meaning it has not yet been approved by regulatory authorities and is still being evaluated for safety and efficacy in patients.
The molecular target of CC-4047 has not been disclosed in the available information. As a small molecule in oncology, it is being investigated for its potential activity in metastatic hormone refractory prostate cancer, but its specific mechanism of action is not publicly detailed.
CC-4047 is being developed by Bristol-Myers Squibb Company, a biopharmaceutical company listed on the New York Stock Exchange under the ticker symbol BMY. The company is conducting clinical research to evaluate the drug's safety and efficacy in patients with prostate cancer.
CC-4047 is in Phase 2 clinical development for prostate cancer. It is an investigational drug, meaning it is not yet approved by the FDA or other regulatory agencies. The Phase 2 trial has been completed, and the drug remains under evaluation for its potential use in treating metastatic hormone refractory prostate cancer.
CC-4047 has been studied in one completed Phase 2 clinical trial, identified by the National Clinical Trial number NCT00072722. This trial evaluated the safety and efficacy of CC-4047 in 36 male patients with metastatic hormone refractory prostate cancer in the United States. The study was uncontrolled and not randomized or double-blinded.
CC-4047 is also known as pomalidomide, an immunomodulatory drug. In the context of prostate cancer research, it has been investigated under the name CC-4047 in a Phase 2 clinical trial for metastatic hormone refractory prostate cancer. The drug is being developed by Bristol-Myers Squibb Company.